Varicose Ulcer Clinical Trial
Official title:
A Randomized, Controlled, Clinical Study to Assess a New Adjustable Compression Device in Patients With Venous Leg Ulcers
Verified date | November 2015 |
Source | 3M |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to evaluate the product performance of a new adjustable compression system for the treatment of venous leg ulcers.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: 1. Is the subject 21 years or older? 2. Does the subject have an active venous leg ulceration? If multiple ulcers are present, the investigator will need to select a single ulcer of the study leg that is > 2cm apart from any other ulcer? 3. Does the subject have an ulcer size between 1cm2 and 12cm2? 4. Does the subject have an ABPI between 0.8 and 1.3 that was taken within the past 28 days? 5. Is the subject ambulatory? 6. Is the subject or family member willing to self-manage the venous leg ulcer therapy at home in collaboration with the medical staff, including the ability to properly readjust the closure straps as indicated by tension indicators, and apply new dressings when needed? 7. Is the subject able to understand questionnaire items and action items (e.g., Subject Diary)? 8. Is the subject willing to give written informed consent, including permission to take photographs of the study leg? Exclusion Criteria: 1. Does the subject have severe arterial occlusive disease? 2. Does the subject have decompensated heart insufficiency NYHA Class IV, ACC.AHA Stage D? 3. Does the subject have septic phlebitis? 4. Does the subject have severe deep vein thrombosis (phlegmasia cerulea dolens) and other conditions contraindicated according to established guidelines and local procedures? 5. Does the subject have known hypersensitivity to any of the component materials? 6. Does the subject have a suspected clinical infection of the ulcer or any other systemic infection (requiring antibiotics)? 7. Is the subject scheduled for surgery for the ulcer during the 12 weeks following inclusion? 8. Does the subject have a hospital stay planned for the 12 weeks following inclusion? 9. Does the subject have a suspected or confirmed cancerous ulceration? 10. Does the subject have severe peripheral sensitive neuropathy? 11. Is the subject participating in any other prospective study interfering with this study? 12. Does the subject have any medical condition which in the professional opinion of the investigator disqualifies the subject from enrollment into the study? 13. Does the subject have a history of noncompliance to therapies? |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Lawson Health Research Institute | London | Ontario |
Canada | Calea Ltd | Mississauga | Ontario |
United States | Institute for Advanced Wound Care | Montgomery | Alabama |
United States | HealthEast Care System | St. Paul | Minnesota |
United States | Jobst Vascular Institute | Toledo | Ohio |
Lead Sponsor | Collaborator |
---|---|
3M |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary efficacy endpoint is the number of ulcers achieving complete closure (100% epithelialization) after 12 weeks | 12 weeks | No | |
Secondary | Wound area reduction and relative wound area reduction at weeks 4, 8, and 12. | Up to 12 weeks | No | |
Secondary | Relative wound area reduction >/= 40% at Week 4 | 4 weeks | No | |
Secondary | Time to complete closure | 1-12 weeks | No | |
Secondary | Occurrence of treatment-related adverse events | 0-12 weeks | Yes | |
Secondary | Occurrence of treatment-related drop-outs | 0-12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05364112 -
Utilization of Compreflex Wraps in Patients With Chronic Venous Insuffciency
|
N/A | |
Completed |
NCT00656383 -
Effectiveness and Efficiency of Two Models of Delivering Care to a Chronic Wound Population
|
N/A | |
Active, not recruiting |
NCT02973893 -
Study of VF001-DP in Patients With Chronic Venous Leg Ulcers
|
Phase 2 | |
Not yet recruiting |
NCT02873728 -
Remote Ischemic Conditioning for Treatment of Chronic Wounds
|
N/A | |
Completed |
NCT01998932 -
Predictive of Biomarkers of Healing in Chronic Venous Ulceration of the Lower Limb
|
N/A | |
Recruiting |
NCT06135246 -
Laser Therapy for Venous Leg Ulcers
|
N/A | |
Active, not recruiting |
NCT03744858 -
The Role of Pyroptosis in Chronic Venous Disease
|
||
Completed |
NCT01449422 -
Clinical Trial to Evaluate the Efficacy, Tolerance and Acceptability of URGO Dressing vs a Hydrofibre in the Local Management of Venous or Predominantly Venous Mixed Leg Ulcers.
|
Phase 4 | |
Completed |
NCT00838500 -
THERMES ET VEINES: Spa for Prevention of Leg Ulcers
|
Phase 3 | |
Completed |
NCT04039789 -
Impact of Physical Activity as a Coadjuvant Treatment in the Healing of Venous Ulcers in Primary Health Care.
|
N/A | |
Completed |
NCT04280679 -
Treatment of Insufficient Superficial and Perforatring Veins of the Lower Limb Using HIFU
|
N/A | |
Completed |
NCT02512159 -
Skin Ulcers Treatment With an Handicraft Topical Device
|
Phase 4 | |
Completed |
NCT02896725 -
Wool-derived Keratin Dressings for Venous Leg Ulcers
|
N/A | |
Completed |
NCT04310280 -
Effects of Local Insulin on Varicose Ulcers for Wound Healing
|
Phase 3 | |
Completed |
NCT02626156 -
Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence
|
Phase 2 | |
Recruiting |
NCT03127904 -
Vein Fitness System vs Compressive Therapy for Venous Ulcers: a Bayesian Adaptive Trial
|
N/A | |
Withdrawn |
NCT00648674 -
A Post-Marketing Clinical Study of Apligraf for Venous Leg Ulcers
|
Phase 4 | |
Terminated |
NCT00727701 -
Study of Individualized Wound Prevention Instruction to Prevent Venous Ulcer Development
|
Phase 1 | |
Completed |
NCT00399308 -
Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers
|
Phase 1/Phase 2 | |
Completed |
NCT00426972 -
Trial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor Sites
|
Phase 3 |